The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Comparative effectiveness of epcoritamab versus real-world usual care in R/R follicular lymphoma
Tycel Phillips, MD, City of Hope, Duarte, CA, discusses a study comparing the effectiveness of epcoritamab versus real-world usual care in relapsed/refractory (R/R) follicular lymphoma (FL). The study found epcoritamab to be particularly effective compared to chemoimmunotherapy, especially in third-line treatment and beyond. However, Dr Phillips suggests that further comparisons should be made with novel treatments like CAR-T therapy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
